hENT1 and Hodgkin lymphoma: not just crossing the channel.

about

hENT1 and Hodgkin lymphoma: not just crossing the channel.

Item

http://www.wikidata.org/entity/Q47565224

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

hENT1 and Hodgkin lymphoma: not just crossing the channel.

@en

hENT1 and Hodgkin lymphoma: not just crossing the channel.

@nl

type

Item

label

hENT1 and Hodgkin lymphoma: not just crossing the channel.

@en

hENT1 and Hodgkin lymphoma: not just crossing the channel.

@nl

prefLabel

hENT1 and Hodgkin lymphoma: not just crossing the channel.

@en

hENT1 and Hodgkin lymphoma: not just crossing the channel.

@nl

P1476

hENT1 and Hodgkin lymphoma: not just crossing the channel.

@en

P2093

Mark Kirschbaum

http://www.w3.org/2001/XMLSchema#string

P2860

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia.

PKC regulation of the human equilibrative nucleoside transporter, hENT1.

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 cor

P304

1024-1025

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190802163297

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18569632

http://www.w3.org/2001/XMLSchema#string